Evidence map›Paper›PMID 41051151›Full record

Observational studyEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2025

Impact of clinical risk characteristics on the prognostic value of high-risk plaques.

Rick H J A Volleberg, Andi Rroku, Jan-Quinten Mol, Renicus S Hermanides, Maarten van Leeuwen, Balázs Berta, Martijn Meuwissen, Fernando Alfonso, Wojciech Wojakowski, Anouar Belkacemi and 5 more

Abstract readObservational Study
In one paragraph

Observational study in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Seeing is believing.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rick H J A VollebergDepartment of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Andi RrokuDepartment of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Berlin, Germany.
Jan-Quinten MolDepartment of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Renicus S HermanidesDepartment of Cardiology, Isala Hospital, Zwolle, the Netherlands.
Maarten van LeeuwenDepartment of Cardiology, Isala Hospital, Zwolle, the Netherlands.
Balázs BertaDepartment of Cardiology, Isala Hospital, Zwolle, the Netherlands.
Martijn MeuwissenDepartment of Cardiology, Amphia Hospital, Breda, the Netherlands.
Fernando AlfonsoDepartment of Cardiology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, CIBER-V, IIS-IP, Madrid, Spain.
Wojciech WojakowskiDivision of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.
Anouar BelkacemiDepartment of Cardiology, AZ West Hospital, Veurne, Belgium.
Giuseppe De LucaDivision of Cardiology, Policlinico "G Martino", University of Messina, Messina, Italy.
Laura RodwellDepartment of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Medical Center, Nijmegen, the Netherlands.
Tomasz RolederFaculty of Medicine, Department of Non-Surgical Clinical Sciences, Wrocław University of Science and Technology (WUST), Wrocław, Poland.
Elvin KedhiMcGill University Health Center, Royal Victoria Hospital, Montreal, Canada.
Niels van RoyenDepartment of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-risk coronary plaques (HRPs) are associated with adverse cardiovascular outcomes. However, the clinical practicality of HRP identification is challenged by their modest prevalence and low positive predictive value.

aimsWe aimed to evaluate the association between clinical risk factors and HRPs, as well as the clinical impact of HRPs across different clinical risk profiles.

methodsThis is a pooled analysis of individual patient data from the prospective observational COMBINE (OCT-FFR) and PECTUS-obs studies. A modified version of the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P) was used for risk stratification. The composite endpoint of major adverse cardiovascular events (MACE) was evaluated on a patient level, and target lesion failure (TLF), also a composite endpoint, was evaluated on a lesion level.

resultsAmong 810 patients, 311, 265, and 234 were at low (TRS-2P 0-1), intermediate (TRS-2P 2), and high risk (TRS-2P ≥3), respectively. The modified TRS-2P had no discriminative value for the identification of patients with an HRP (area under the receiver operating characteristic curve 0.51, 95% confidence interval [CI]: 0.47-0.56). A consistent trend towards worse clinical outcome in the presence of an HRP was observed across different clinical risk profiles (p

conclusionsHRPs are associated with a negative clinical outcome, without apparent differences between clinical risk profiles. This highlights the independent value of optical coherence tomography for prognostication beyond clinical risk factors. The high event rates in high-risk patients with HRPs necessitate the search for additional therapeutic strategies to mitigate this risk.

Indexed as

Coronary Artery DiseasePlaque, AtheroscleroticAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk Factors

Identifiers

PMID41051151
PMCPMC12477505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.